Schifferli J A, Steiger G, Hauptmann G, Spaeth P J, Sjöholm A G
J Clin Invest. 1985 Dec;76(6):2127-33. doi: 10.1172/JCI112217.
To examine whether the ability of complement to form soluble immune complexes plays a role in preventing immune complex-mediated diseases, we analyzed the capacity of complement to inhibit immune precipitation (IIP) and to solubilize preformed immune aggregates (SOL) in 23 sera of patients with various hypocomplementemic states, and we correlated the results of these studies with the clinical syndromes found in the various patients. In sera with deficiency or depletion of early classical pathway components, IIP was profoundly altered, whereas SOL was delayed but in the normal range. In contrast, in sera with C3 depletion but intact classical pathway and in properdin-deficient serum, IIP was initially preserved, whereas SOL was abolished. Since the incidence of immune complex diseases in various hypocomplementemic states correlates with the severity of IIP defects, but not with reduced SOL, it is suggested that IIP is an essential biological function of complement that prevents the rapid formation of insoluble immune complexes in vivo.
为了研究补体形成可溶性免疫复合物的能力是否在预防免疫复合物介导的疾病中发挥作用,我们分析了补体在23例各种低补体血症状态患者血清中抑制免疫沉淀(IIP)和溶解预先形成的免疫聚集体(SOL)的能力,并将这些研究结果与不同患者中发现的临床综合征相关联。在早期经典途径成分缺乏或耗竭的血清中,IIP发生了深刻改变,而SOL虽有延迟但在正常范围内。相反,在C3耗竭但经典途径完整的血清和备解素缺乏的血清中,IIP最初得以保留,而SOL则被消除。由于各种低补体血症状态下免疫复合物疾病的发生率与IIP缺陷的严重程度相关,而与SOL降低无关,因此提示IIP是补体的一项重要生物学功能,可防止体内不溶性免疫复合物的快速形成。